Enhancing our understanding of the cellular pathways linked to PTLD development is not only a matter of academic interest, but also holds promise for innovative treatment strategies, such as the use of JAK/STAT inhibitors [28,29]. This evidence concerns the gene SOAT1 and post-transplant lymphoproliferative disease.